机构：[1]Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[2]Department of Psychiatry, Sichuan Clinical Medical Research Center for Mental Disorder, Chengdu, Sichuan, China.[3]Department of Psychiatry, The Fourth People's Hospital of Chengdu, Chengdu, Sichuan, China.[4]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[5]Institute for Systematic Genetics, Frontiers Science Center for Disease-Related Molecular Network, Chengdu, Sichuan, China.
The purpose of this study was to investigate the relationship between childhood chronic stress(CCS), Protein kinase C beta (PRKCB) methylation and adolescent major depressive disorder (MDD). After recruiting 100 adolescents with MDD and 50 healthy controls (HCs), we evaluated the severity of CCS. PRKCB methylation was assessed by pyrosequencing using whole blood-derived DNA. To explore the relationship between CCS, PRKCB and adolescent MDD, we conducted correlation analysis and regression analysis, and constructed multiplicative interaction models and generalized linear models. PRKCB methylation and CCS were both found to be associated with MDD, and CCS was associated with PRKCB methylation. No significant CCS-PRKCB methylation interactions were observed. However, we found the interaction of CCS and MDD on PRKCB methylation. Our results found that PRKCB methylation was influenced by CCS and the disease itself, and PRKCB methylation was significantly positively associated with MDD severity, suggesting that PRKCB methylation may be a potential biomarker for adolescent MDD. This study is a cross-sectional observational study, which cannot draw the conclusion of causality. Prospective cohort studies are needed to further examine the relationship between CCS, adolescent MDD, and PRKCB methylation.
基金：
This work was supported by the National key R&D program of Chinese Science & Technology Department [2023YFE0118600], National Natural Science Foundation of China [81801357], Science & Technology Department of Sichuan Province [2022YFS0351 & 2020JDKP0013], Health Commission of Sichuan province program [21PJ020], Science and Technology Department of Chengdu [2019-YF05-00284- SN].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区生物学
小类|3 区生化与分子生物学3 区遗传学
最新[2023]版：
大类|3 区生物学
小类|3 区生化与分子生物学3 区遗传学
第一作者：
第一作者机构：[1]Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan, China.[2]Department of Psychiatry, Sichuan Clinical Medical Research Center for Mental Disorder, Chengdu, Sichuan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan, China.[2]Department of Psychiatry, Sichuan Clinical Medical Research Center for Mental Disorder, Chengdu, Sichuan, China.[5]Institute for Systematic Genetics, Frontiers Science Center for Disease-Related Molecular Network, Chengdu, Sichuan, China.
推荐引用方式(GB/T 7714)：
Tao Yuanmei,Jin Meijiang,Zhang Hang,et al.PRKCB methylation: a potential biomarker of MDD with childhood chronic stress, a cross-sectional study in drug-naive, first-episode adolescent MDD[J].Epigenetics.2024,19(1):2408159.doi:10.1080/15592294.2024.2408159.
APA：
Tao Yuanmei,Jin Meijiang,Zhang Hang,Ran Maojia,Xu Hanmei...&Yin Li.(2024).PRKCB methylation: a potential biomarker of MDD with childhood chronic stress, a cross-sectional study in drug-naive, first-episode adolescent MDD.Epigenetics,19,(1)
MLA：
Tao Yuanmei,et al."PRKCB methylation: a potential biomarker of MDD with childhood chronic stress, a cross-sectional study in drug-naive, first-episode adolescent MDD".Epigenetics 19..1(2024):2408159
